Related Experiment Video

Updated: Jun 23, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

The Role of Early Molecular Response in the Management of Chronic Phase CML

Patrick Harrington1,2, Aytug Kizilors2,3, Hugues de Lavallade4,5

  • 1Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.

Current Hematologic Malignancy Reports
|April 14, 2017
PubMed
Abstract

Insights

Identifying poor tyrosine kinase inhibitor (TKI) responders in chronic myeloid leukemia is crucial. Early molecular response (EMR) at 3 months is a key indicator, but refining its predictive accuracy is needed for better patient outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Tyrosine kinase inhibitors (TKIs) have significantly improved outcomes for chronic myeloid leukemia (CML) patients.
  • Identifying patients with suboptimal response to TKIs early is critical to prevent disease progression.

Purpose of the Study:

  • To review evidence on the impact of early response to TKIs in CML.
  • To discuss the utility and limitations of early molecular response (EMR) in predicting TKI response.

Main Methods:

  • Review of past and recent scientific literature on TKI response in CML.
  • Analysis of the definition and predictive value of EMR (3-month BCR-ABL1 transcript <10% IS).

Main Results:

  • EMR is a valuable tool for identifying CML patients at higher risk of progression.
  • The specificity of EMR in predicting progression can be limited.
  • Improving specificity may involve assessing the rate of BCR-ABL1 transcript decline (halving time or velocity).

Conclusions:

  • Standardizing metrics like halving time could enhance clinical recommendations for TKI therapy.
  • Refined early response criteria may lead to modified clinical practices and improved CML management.
Keywords:
CMLChronic myeloid leukemiasEarly molecular responseTyrosine kinase inhibitors

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Related Concept Videos

Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...